Main Logo
+17162654855
[email protected]

Cyclosporine Drugs Industry Decade Long Trends, Analysis and Forecast 2026-2034

Cyclosporine Drugs Industry by Indication (Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Autoimmune Myasthenia Gravis, Dry Eye, Others), by Route of Administration (Oral, Parenteral), by North America (United States, Canada, Mexico), by Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), by Asia Pacific (China, Japan, India, Australia, South Korea, Rest of Asia Pacific), by Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), by South America (Brazil, Argentina, Rest of South America) Forecast 2026-2034

Base Year: 2025
234 Pages
Main Logo

Cyclosporine Drugs Industry Decade Long Trends, Analysis and Forecast 2026-2034

About Precision Market View

Precision Market View offers precise market research, industry intelligence, and data analysis for healthcare, manufacturing, technology, and energy. Our reports provide the clarity you need to make informed decisions and drive growth.

Our team combines primary research, advanced analytics, and industry expertise to deliver actionable intelligence. We offer syndicated reports, custom research, and consulting services tailored to your business needs.

At Precision Market View, we are committed to quality, transparency, and client satisfaction. Every report is rigorously validated to ensure accuracy and relevance. Our global perspective and local expertise help you understand both the big picture and the finer details of your market.

Stay informed with Precision Market View. Subscribe to our newsletter for the latest updates and research highlights, and follow us on social media for real-time insights.

Precision Market View – Clarity for Your Strategic Decisions.

Geographic Coverage of Cyclosporine Drugs Industry

Higher Coverage
Lower Coverage
No Coverage

Cyclosporine Drugs Industry REPORT HIGHLIGHTS

AspectsDetails
Study Period 2020-2034
Base Year 2025
Estimated Year 2026
Forecast Period2026-2034
Historical Period2020-2025
Growth RateCAGR of 14.76% from 2020-2034
Segmentation
    • By Indication
      • Transplant Rejection Prophylaxis
      • Rheumatoid Arthritis
      • Psoriasis
      • Autoimmune Myasthenia Gravis
      • Dry Eye
      • Others
    • By Route of Administration
      • Oral
      • Parenteral
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Table of Contents

  1. 1. Introduction
    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Objective
    • 1.4. Definitions and Assumptions
  2. 2. Executive Summary
    • 2.1. Market Snapshot
  3. 3. Market Dynamics
    • 3.1. Market Drivers
    • 3.2. Market Restrains
    • 3.3. Market Trends
    • 3.4. Market Opportunities
  4. 4. Market Factor Analysis
    • 4.1. Porters Five Forces
      • 4.1.1. Bargaining Power of Suppliers
      • 4.1.2. Bargaining Power of Buyers
      • 4.1.3. Threat of New Entrants
      • 4.1.4. Threat of Substitutes
      • 4.1.5. Competitive Rivalry
    • 4.2. PESTEL analysis
    • 4.3. BCG Analysis
      • 4.3.1. Stars (High Growth, High Market Share)
      • 4.3.2. Cash Cows (Low Growth, High Market Share)
      • 4.3.3. Question Mark (High Growth, Low Market Share)
      • 4.3.4. Dogs (Low Growth, Low Market Share)
    • 4.4. Ansoff Matrix Analysis
    • 4.5. Supply Chain Analysis
    • 4.6. Regulatory Landscape
    • 4.7. Current Market Potential and Opportunity Assessment (TAM–SAM–SOM Framework)
    • 4.8. PMV Analyst Note
  5. 5. Market Analysis, Insights and Forecast 2021-2033
    • 5.1. Market Analysis, Insights and Forecast - by Indication
      • 5.1.1. Transplant Rejection Prophylaxis
      • 5.1.2. Rheumatoid Arthritis
      • 5.1.3. Psoriasis
      • 5.1.4. Autoimmune Myasthenia Gravis
      • 5.1.5. Dry Eye
      • 5.1.6. Others
    • 5.2. Market Analysis, Insights and Forecast - by Route of Administration
      • 5.2.1. Oral
      • 5.2.2. Parenteral
    • 5.3. Market Analysis, Insights and Forecast - by Region
      • 5.3.1. North America
      • 5.3.2. Europe
      • 5.3.3. Asia Pacific
      • 5.3.4. Middle East and Africa
      • 5.3.5. South America
  6. 6. Global Cyclosporine Drugs Industry Analysis, Insights and Forecast, 2021-2033
    • 6.1. Market Analysis, Insights and Forecast - by Indication
      • 6.1.1. Transplant Rejection Prophylaxis
      • 6.1.2. Rheumatoid Arthritis
      • 6.1.3. Psoriasis
      • 6.1.4. Autoimmune Myasthenia Gravis
      • 6.1.5. Dry Eye
      • 6.1.6. Others
    • 6.2. Market Analysis, Insights and Forecast - by Route of Administration
      • 6.2.1. Oral
      • 6.2.2. Parenteral
  7. 7. North America Cyclosporine Drugs Industry Analysis, Insights and Forecast, 2020-2032
    • 7.1. Market Analysis, Insights and Forecast - by Indication
      • 7.1.1. Transplant Rejection Prophylaxis
      • 7.1.2. Rheumatoid Arthritis
      • 7.1.3. Psoriasis
      • 7.1.4. Autoimmune Myasthenia Gravis
      • 7.1.5. Dry Eye
      • 7.1.6. Others
    • 7.2. Market Analysis, Insights and Forecast - by Route of Administration
      • 7.2.1. Oral
      • 7.2.2. Parenteral
  8. 8. Europe Cyclosporine Drugs Industry Analysis, Insights and Forecast, 2020-2032
    • 8.1. Market Analysis, Insights and Forecast - by Indication
      • 8.1.1. Transplant Rejection Prophylaxis
      • 8.1.2. Rheumatoid Arthritis
      • 8.1.3. Psoriasis
      • 8.1.4. Autoimmune Myasthenia Gravis
      • 8.1.5. Dry Eye
      • 8.1.6. Others
    • 8.2. Market Analysis, Insights and Forecast - by Route of Administration
      • 8.2.1. Oral
      • 8.2.2. Parenteral
  9. 9. Asia Pacific Cyclosporine Drugs Industry Analysis, Insights and Forecast, 2020-2032
    • 9.1. Market Analysis, Insights and Forecast - by Indication
      • 9.1.1. Transplant Rejection Prophylaxis
      • 9.1.2. Rheumatoid Arthritis
      • 9.1.3. Psoriasis
      • 9.1.4. Autoimmune Myasthenia Gravis
      • 9.1.5. Dry Eye
      • 9.1.6. Others
    • 9.2. Market Analysis, Insights and Forecast - by Route of Administration
      • 9.2.1. Oral
      • 9.2.2. Parenteral
  10. 10. Middle East and Africa Cyclosporine Drugs Industry Analysis, Insights and Forecast, 2020-2032
    • 10.1. Market Analysis, Insights and Forecast - by Indication
      • 10.1.1. Transplant Rejection Prophylaxis
      • 10.1.2. Rheumatoid Arthritis
      • 10.1.3. Psoriasis
      • 10.1.4. Autoimmune Myasthenia Gravis
      • 10.1.5. Dry Eye
      • 10.1.6. Others
    • 10.2. Market Analysis, Insights and Forecast - by Route of Administration
      • 10.2.1. Oral
      • 10.2.2. Parenteral
  11. 11. South America Cyclosporine Drugs Industry Analysis, Insights and Forecast, 2020-2032
    • 11.1. Market Analysis, Insights and Forecast - by Indication
      • 11.1.1. Transplant Rejection Prophylaxis
      • 11.1.2. Rheumatoid Arthritis
      • 11.1.3. Psoriasis
      • 11.1.4. Autoimmune Myasthenia Gravis
      • 11.1.5. Dry Eye
      • 11.1.6. Others
    • 11.2. Market Analysis, Insights and Forecast - by Route of Administration
      • 11.2.1. Oral
      • 11.2.2. Parenteral
  12. 12. Competitive Analysis
      • 12.1. Company Profiles
        • 12.1.1 Teva Pharmaceutical Industries Ltd
          • 12.1.1.1. Company Overview
          • 12.1.1.2. Products
          • 12.1.1.3. Company Financials
          • 12.1.1.4. SWOT Analysis
        • 12.1.2 Novartis AG
          • 12.1.2.1. Company Overview
          • 12.1.2.2. Products
          • 12.1.2.3. Company Financials
          • 12.1.2.4. SWOT Analysis
        • 12.1.3 AbbVie Inc
          • 12.1.3.1. Company Overview
          • 12.1.3.2. Products
          • 12.1.3.3. Company Financials
          • 12.1.3.4. SWOT Analysis
        • 12.1.4 Strides Pharma Science Limited
          • 12.1.4.1. Company Overview
          • 12.1.4.2. Products
          • 12.1.4.3. Company Financials
          • 12.1.4.4. SWOT Analysis
        • 12.1.5 McKesson Medical-Surgical Inc
          • 12.1.5.1. Company Overview
          • 12.1.5.2. Products
          • 12.1.5.3. Company Financials
          • 12.1.5.4. SWOT Analysis
        • 12.1.6 EonLabs
          • 12.1.6.1. Company Overview
          • 12.1.6.2. Products
          • 12.1.6.3. Company Financials
          • 12.1.6.4. SWOT Analysis
        • 12.1.7 Sun Pharmaceutical Industries Ltd
          • 12.1.7.1. Company Overview
          • 12.1.7.2. Products
          • 12.1.7.3. Company Financials
          • 12.1.7.4. SWOT Analysis
        • 12.1.8 Mayne Pharma Group Limited
          • 12.1.8.1. Company Overview
          • 12.1.8.2. Products
          • 12.1.8.3. Company Financials
          • 12.1.8.4. SWOT Analysis
        • 12.1.9 Apotex Inc
          • 12.1.9.1. Company Overview
          • 12.1.9.2. Products
          • 12.1.9.3. Company Financials
          • 12.1.9.4. SWOT Analysis
        • 12.1.10 Santen Pharmaceutical Co Ltd
          • 12.1.10.1. Company Overview
          • 12.1.10.2. Products
          • 12.1.10.3. Company Financials
          • 12.1.10.4. SWOT Analysis
      • 12.2. Market Entropy
        • 12.2.1 Company's Key Areas Served
        • 12.2.2 Recent Developments
      • 12.3. Company Market Share Analysis 2025
        • 12.3.1 Top 5 Companies Market Share Analysis
        • 12.3.2 Top 3 Companies Market Share Analysis
    • 12.4. List of Potential Customers
  13. 13. Research Methodology

    List of Figures

    1. Figure 1: Global Cyclosporine Drugs Industry Revenue Breakdown (billion, %) by Region 2025 & 2033
    2. Figure 2: North America Cyclosporine Drugs Industry Revenue (billion), by Indication 2025 & 2033
    3. Figure 3: North America Cyclosporine Drugs Industry Revenue Share (%), by Indication 2025 & 2033
    4. Figure 4: North America Cyclosporine Drugs Industry Revenue (billion), by Route of Administration 2025 & 2033
    5. Figure 5: North America Cyclosporine Drugs Industry Revenue Share (%), by Route of Administration 2025 & 2033
    6. Figure 6: North America Cyclosporine Drugs Industry Revenue (billion), by Country 2025 & 2033
    7. Figure 7: North America Cyclosporine Drugs Industry Revenue Share (%), by Country 2025 & 2033
    8. Figure 8: Europe Cyclosporine Drugs Industry Revenue (billion), by Indication 2025 & 2033
    9. Figure 9: Europe Cyclosporine Drugs Industry Revenue Share (%), by Indication 2025 & 2033
    10. Figure 10: Europe Cyclosporine Drugs Industry Revenue (billion), by Route of Administration 2025 & 2033
    11. Figure 11: Europe Cyclosporine Drugs Industry Revenue Share (%), by Route of Administration 2025 & 2033
    12. Figure 12: Europe Cyclosporine Drugs Industry Revenue (billion), by Country 2025 & 2033
    13. Figure 13: Europe Cyclosporine Drugs Industry Revenue Share (%), by Country 2025 & 2033
    14. Figure 14: Asia Pacific Cyclosporine Drugs Industry Revenue (billion), by Indication 2025 & 2033
    15. Figure 15: Asia Pacific Cyclosporine Drugs Industry Revenue Share (%), by Indication 2025 & 2033
    16. Figure 16: Asia Pacific Cyclosporine Drugs Industry Revenue (billion), by Route of Administration 2025 & 2033
    17. Figure 17: Asia Pacific Cyclosporine Drugs Industry Revenue Share (%), by Route of Administration 2025 & 2033
    18. Figure 18: Asia Pacific Cyclosporine Drugs Industry Revenue (billion), by Country 2025 & 2033
    19. Figure 19: Asia Pacific Cyclosporine Drugs Industry Revenue Share (%), by Country 2025 & 2033
    20. Figure 20: Middle East and Africa Cyclosporine Drugs Industry Revenue (billion), by Indication 2025 & 2033
    21. Figure 21: Middle East and Africa Cyclosporine Drugs Industry Revenue Share (%), by Indication 2025 & 2033
    22. Figure 22: Middle East and Africa Cyclosporine Drugs Industry Revenue (billion), by Route of Administration 2025 & 2033
    23. Figure 23: Middle East and Africa Cyclosporine Drugs Industry Revenue Share (%), by Route of Administration 2025 & 2033
    24. Figure 24: Middle East and Africa Cyclosporine Drugs Industry Revenue (billion), by Country 2025 & 2033
    25. Figure 25: Middle East and Africa Cyclosporine Drugs Industry Revenue Share (%), by Country 2025 & 2033
    26. Figure 26: South America Cyclosporine Drugs Industry Revenue (billion), by Indication 2025 & 2033
    27. Figure 27: South America Cyclosporine Drugs Industry Revenue Share (%), by Indication 2025 & 2033
    28. Figure 28: South America Cyclosporine Drugs Industry Revenue (billion), by Route of Administration 2025 & 2033
    29. Figure 29: South America Cyclosporine Drugs Industry Revenue Share (%), by Route of Administration 2025 & 2033
    30. Figure 30: South America Cyclosporine Drugs Industry Revenue (billion), by Country 2025 & 2033
    31. Figure 31: South America Cyclosporine Drugs Industry Revenue Share (%), by Country 2025 & 2033

    List of Tables

    1. Table 1: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Indication 2020 & 2033
    2. Table 2: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
    3. Table 3: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Region 2020 & 2033
    4. Table 4: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Indication 2020 & 2033
    5. Table 5: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
    6. Table 6: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Country 2020 & 2033
    7. Table 7: United States Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    8. Table 8: Canada Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    9. Table 9: Mexico Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    10. Table 10: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Indication 2020 & 2033
    11. Table 11: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
    12. Table 12: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Country 2020 & 2033
    13. Table 13: Germany Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    14. Table 14: United Kingdom Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    15. Table 15: France Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    16. Table 16: Italy Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    17. Table 17: Spain Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    18. Table 18: Rest of Europe Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    19. Table 19: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Indication 2020 & 2033
    20. Table 20: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
    21. Table 21: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Country 2020 & 2033
    22. Table 22: China Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    23. Table 23: Japan Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    24. Table 24: India Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    25. Table 25: Australia Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    26. Table 26: South Korea Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    27. Table 27: Rest of Asia Pacific Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    28. Table 28: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Indication 2020 & 2033
    29. Table 29: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
    30. Table 30: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Country 2020 & 2033
    31. Table 31: GCC Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    32. Table 32: South Africa Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    33. Table 33: Rest of Middle East and Africa Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    34. Table 34: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Indication 2020 & 2033
    35. Table 35: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
    36. Table 36: Global Cyclosporine Drugs Industry Revenue billion Forecast, by Country 2020 & 2033
    37. Table 37: Brazil Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    38. Table 38: Argentina Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033
    39. Table 39: Rest of South America Cyclosporine Drugs Industry Revenue (billion) Forecast, by Application 2020 & 2033

    Frequently Asked Questions

    1. What is the projected Compound Annual Growth Rate (CAGR) of the Cyclosporine Drugs Industry?

    The projected CAGR is approximately 14.76%.

    2. Which companies are prominent players in the Cyclosporine Drugs Industry?

    Key companies in the market include Teva Pharmaceutical Industries Ltd, Novartis AG, AbbVie Inc, Strides Pharma Science Limited, McKesson Medical-Surgical Inc, EonLabs, Sun Pharmaceutical Industries Ltd, Mayne Pharma Group Limited, Apotex Inc, Santen Pharmaceutical Co Ltd.

    3. What are the main segments of the Cyclosporine Drugs Industry?

    The market segments include Indication, Route of Administration.

    4. Can you provide details about the market size?

    The market size is estimated to be USD 9.44 billion as of 2022.

    5. What are some drivers contributing to market growth?

    Growing Prevalence of Target Disease; Increase in Potential Clinical Pipeline Candidates; Well-Defined Regulatory Guidelines.

    6. What are the notable trends driving market growth?

    Rheumatoid Arthritis Indication and is Expected to Grow Over the Forecast Period.

    7. Are there any restraints impacting market growth?

    Lack of Awareness of Target Disease In Developing Regions.

    8. Can you provide examples of recent developments in the market?

    August 2022 : Strides Pharma Science Limited received approval for Cyclosporine Softgel Capsules USP (Modified), 25 mg, 50 mg, and 100 mg from the United States FDA. Cyclosporine is prescribed for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. It is also used to treat severe rheumatoid arthritis and psoriasis.

    9. What pricing options are available for accessing the report?

    Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.

    10. Is the market size provided in terms of value or volume?

    The market size is provided in terms of value, measured in billion.

    11. Are there any specific market keywords associated with the report?

    Yes, the market keyword associated with the report is "Cyclosporine Drugs Industry," which aids in identifying and referencing the specific market segment covered.

    12. How do I determine which pricing option suits my needs best?

    The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.

    13. Are there any additional resources or data provided in the Cyclosporine Drugs Industry report?

    While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.

    14. How can I stay updated on further developments or reports in the Cyclosporine Drugs Industry?

    To stay informed about further developments, trends, and reports in the Cyclosporine Drugs Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.

    Methodology

    Step 1 - Identification of Relevant Samples Size from Population Database

    Step Chart
    Bar Chart
    Method Chart

    Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

    Approach Chart
    Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.

    Note*: In applicable scenarios

    Step 3 - Data Sources

    Primary Research

    • Web Analytics
    • Survey Reports
    • Research Institute
    • Latest Research Reports
    • Opinion Leaders

    Secondary Research

    • Annual Reports
    • White Paper
    • Latest Press Release
    • Industry Association
    • Paid Database
    • Investor Presentations
    Analyst Chart

    Step 4 - Data Triangulation

    Involves using different sources of information in order to increase the validity of a study

    These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.

    Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.

    During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence

    Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.